
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/958318/publications.pdf Version: 2024-02-01



LILLE KANTED

#	Article	IF	CITATIONS
1	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Advances, 2022, 6, 1243-1254.	5.2	19
2	Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 617-628.	27.0	144
3	Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 138-147.	27.0	86
4	GRNDaD: big data and sickle cell disease. Blood Advances, 2022, 6, 1088-1088.	5.2	4
5	Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. American Journal of Hematology, 2022, 97, 603-612.	4.1	25
6	Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE, 2022, 17, e0265342.	2.5	13
7	Genotype-phenotype and outcome associations in patients with Fanconi anemia: The National Cancer Institute cohort. Haematologica, 2022, , .	3.5	0
8	Confirmation of the utility of the Wells' Score for pulmonary embolism in patients with sickle cell disease. Journal of Thrombosis and Thrombolysis, 2022, , .	2.1	1
9	Multiâ€organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease. American Journal of Hematology, 2022, 97, .	4.1	2
10	Emergency department utilization for sickle cell disease in St. Vincent and the Grenadines. Pan African Medical Journal, 2021, 38, 100.	0.8	0
11	Feasibility of an mHealth self-management intervention for children and adolescents with sickle cell disease and their families. Translational Behavioral Medicine, 2021, 11, 724-732.	2.4	7
12	Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease. International Journal of Laboratory Hematology, 2021, 43, O168-O170.	1.3	0
13	Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia: Results From the DISPLACE Study. Journal of Pediatric Hematology/Oncology, 2021, 43, e1062-e1068.	0.6	20
14	48847 Assessing Transition Outcomes in Sickle Cell Disease (SCD) Prior To Implementation of A Formal Transition Program. Journal of Clinical and Translational Science, 2021, 5, 127-128.	0.6	0
15	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
16	Kneeling Was the First Step for Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, 1004-1005.	3.9	4
17	Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium. Implementation Science Communications, 2021, 2, 87.	2.2	1
18	Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€~realâ€world' report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160.	2.5	4

#	Article	IF	CITATIONS
19	Which adults with sickle cell disease need an evaluation for pulmonary embolism?. British Journal of Haematology, 2021, 195, 447-455.	2.5	4
20	American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Advances, 2021, 5, 3668-3689.	5.2	38
21	One Small Step for Sickle Cell Disease: Many More to Go. Annals of Internal Medicine, 2021, 174, 1313-1314.	3.9	0
22	Annals On Call - Vascular Occlusive Crisis: Site of Care Matters. Annals of Internal Medicine, 2021, 174, OC1.	3.9	0
23	Improving Outcomes for Patients With Sickle Cell Disease in the United States. JAMA Health Forum, 2021, 2, e213467.	2.2	17
24	Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast. European Heart Journal - Case Reports, 2021, 5, ytaa555.	0.6	3
25	Changes in Care Delivery for Children With Sickle Cell Anemia During the COVID-19 Pandemic. Journal of Pediatric Hematology/Oncology, 2021, 43, e1231-e1234.	0.6	0
26	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood, 2021, 138, 12-12.	1.4	5
27	Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open, 2021, 11, e050880.	1.9	18
28	Association Between Patent Foramen Ovale and Overt Ischemic Stroke in Children With Sickle Cell Disease. Frontiers in Neurology, 2021, 12, 761443.	2.4	1
29	Gene therapy for sickle cell disease: where we are now?. Hematology American Society of Hematology Education Program, 2021, 2021, 174-180.	2.5	18
30	Innovations in Targeted Antiâ€Adhesion Treatment for Sickle Cell Disease. Clinical Pharmacology and Therapeutics, 2020, 107, 140-146.	4.7	4
31	Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium. Pediatric Blood and Cancer, 2020, 67, e28172.	1.5	5
32	An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathy. Radiology Case Reports, 2020, 15, 26-30.	0.6	0
33	Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	2.5	22
34	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063.	5.2	93
35	Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813.	5.2	57
36	Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium. Pediatric Blood and Cancer, 2020, 67, e28569.	1.5	2

#	Article	IF	CITATIONS
37	A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Annals of Emergency Medicine, 2020, 76, S64-S72.	0.6	22
38	<p>Development of a Severity Classification System for Sickle Cell Disease</p> . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633.	1.9	12
39	Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care. JAMA Network Open, 2020, 3, e206016.	5.9	30
40	Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multiâ€center <scp>HGB</scp> â€206 trial. American Journal of Hematology, 2020, 95, E239-E242.	4.1	22
41	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood, 2020, 136, 623-626.	1.4	26
42	Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet Journal of Rare Diseases, 2020, 15, 178.	2.7	21
43	Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study. Blood, 2020, 136, 17-19.	1.4	2
44	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	1.4	0
45	Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. Blood, 2020, 136, 33-33.	1.4	1
46	Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry. Blood, 2020, 136, 3-3.	1.4	0
47	Assessment of Impact of a mHealth Self-Management Intervention for Children with Sickle Cell Disease. Blood, 2020, 136, 11-12.	1.4	0
48	Evaluation of STOP Protocol Implementation for Abnormal TCD in Children with Sickle Cell Anemia at Risk for Stroke: Displace Consortium. Blood, 2020, 136, 22-23.	1.4	0
49	Sickle Stroke Screen: A Patient-Centered Educational Initiative for Children with Sickle Cell Anemia in the Displace Consortium. Blood, 2020, 136, 43-44.	1.4	0
50	Effect of Sickle Cell Related Therapies on Growth in Children with Sickle Cell Disease: Evidence from the Displace Study. Blood, 2020, 136, 21-21.	1.4	0
51	Sex Based Differences in Sickle Cell Disease. Blood, 2020, 136, 37-37.	1.4	0
52	An approach to revising mHealth interventions for children and families: A case example in sickle cell disease. Research in Nursing and Health, 2019, 42, 483-493.	1.6	4
53	Ischemic stroke in children and young adults with sickle cell disease in the postâ€&TOP era. American Journal of Hematology, 2019, 94, 1335-1343.	4.1	33
54	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemporary Clinical Trials, 2019, 85, 105835.	1.8	6

#	Article	IF	CITATIONS
55	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
56	Barriers to Pediatric Sickle Cell Disease Guideline Recommendations. Global Pediatric Health, 2019, 6, 2333794X1984702.	0.7	25
57	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematology,the, 2019, 6, e585-e596.	4.6	128
58	Childhood Hearing Loss in Patients With Sickle Cell Disease in the United States. Journal of Pediatric Hematology/Oncology, 2019, 41, 124-128.	0.6	10
59	International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease. Journal of Clinical Medicine, 2019, 8, 2136.	2.4	4
60	Health-related Quality of Life in Children With Sickle Cell Disease Undergoing Chronic Red Cell Transfusion Therapy. Journal of Pediatric Hematology/Oncology, 2019, 41, 307-312.	0.6	11
61	Ticagrelor does not impact patientâ€reported pain in young adults with sickle cell disease: a multicentre, randomised phase <scp>II</scp> b study. British Journal of Haematology, 2019, 184, 269-278.	2.5	20
62	Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. American Journal of Hematology, 2019, 94, 55-61.	4.1	78
63	Novel findings from the multinational <scp>DOVE</scp> study on geographic and ageâ€related differences in pain perception and analgesic usage in children with sickle cell anaemia. British Journal of Haematology, 2019, 184, 1058-1061.	2.5	13
64	Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies. Blood, 2019, 134, 991-991.	1.4	5
65	Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood, 2019, 134, 2061-2061.	1.4	7
66	The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy. Blood, 2019, 134, 206-206.	1.4	7
67	High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study. Journal of Health Economics and Outcomes Research, 2019, 6, 174-184.	1.2	10
68	Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium. Blood, 2019, 134, 2270-2270.	1.4	0
69	Barriers and Facilitators to Transcranial Doppler Screening for Stroke Prevention in Children with Sickle Cell Anemia: Results from the Displace Consortium. Blood, 2019, 134, 3393-3393.	1.4	2
70	Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study. Blood, 2019, 134, 2289-2289.	1.4	5
71	The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395.	4.1	52
72	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances, 2018, 2, 1969-1979.	5.2	29

#	Article	IF	CITATIONS
73	The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2897-2904.	1.6	22
74	Opioid utilization patterns in United States individuals with sickle cell disease. American Journal of Hematology, 2018, 93, E345-E347.	4.1	29
75	A Phase 3 Trial of <scp>l</scp> -Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235.	27.0	378
76	Incomplete implementation of guidelineâ€based stroke prevention therapy in sickle cell disease. American Journal of Hematology, 2018, 93, E222-E224.	4.1	1
77	Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial. Blood, 2018, 132, 1080-1080.	1.4	11
78	Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. Blood, 2018, 132, 1026-1026.	1.4	23
79	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505.	1.4	3
80	Mind Over Matter: One Person's Journey From Patient to Change-Maker. , 2018, 15, .		1
81	Transfusion Practices Among Hematology/Oncology Healthcare Professionals. Blood, 2018, 132, 2552-2552.	1.4	0
82	Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study. Blood, 2018, 132, 1082-1082.	1.4	1
83	Results from the Displace Consortium: Practice Patterns on the Use of Transcranial Doppler Screening for Risk of Stroke in Children with Sickle Cell Anemia. Blood, 2018, 132, 4697-4697.	1.4	0
84	Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke. Stroke, 2017, 48, 686-691.	2.0	22
85	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 429-439.	27.0	599
86	Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4782-E4791.	7.1	40
87	Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program. Global Pediatric Health, 2017, 4, 2333794X1773919.	0.7	3
88	Increased prevalence of potential rightâ€ŧoâ€ŀeft shunting in children with sickle cell anaemia and stroke. British Journal of Haematology, 2017, 176, 300-308.	2.5	31
89	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588.	3.4	14
90	Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease. Blood, 2017, 130, 990-990.	1.4	16

#	Article	IF	CITATIONS
91	Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia. PLoS ONE, 2016, 11, e0144901.	2.5	33
92	Transcranial doppler reâ€screening of subjects who participated in STOP and STOP II. American Journal of Hematology, 2016, 91, 1191-1194.	4.1	17
93	Needs Assessment for Patients with Sickle Cell Disease in South Carolina, 2012. Public Health Reports, 2016, 131, 108-116.	2.5	10
94	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	27.0	117
95	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Blood, 2016, 128, 1-1.	1.4	16
96	Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176.	1.4	42
97	Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study. Blood, 2016, 128, 3654-3654.	1.4	2
98	Validation of a novel point of care testing device for sickle cell disease. BMC Medicine, 2015, 13, 225.	5.5	81
99	When Is the Optimal Time to Screen for Chlamydia in Adolescents and Young Adults With Sickle Cell Disease?. Clinical Pediatrics, 2015, 54, 149-151.	0.8	0
100	Using Fludarabine to Reduce Exposure to Alkylating Agents in Children with Sickle Cell Disease Receiving Busulfan, Cyclophosphamide, and Antithymocyte Globulin Transplant Conditioning: Results of a Dose De-Escalation Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 900-905.	2.0	24
101	Moyamoya Disease Predicts Progression of Cerebral Vasculopathy in Patients with Sickle Cell Disease Despite Chronic Transfusion Therapy. Blood, 2015, 126, 2071-2071.	1.4	2
102	Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease. Blood, 2015, 126, 3233-3233.	1.4	11
103	Impact of TCD Screening Protocol on the Incidence of Hemorrhagic Stroke in Children and Young Adults with Sickle Cell Disease. Blood, 2015, 126, 3402-3402.	1.4	5
104	Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP Era. Blood, 2015, 126, 68-68.	1.4	5
105	Barriers to Implementation of Evidence-Based Stroke Prevention in Sickle Cell Disease: A Preliminary Study. Blood, 2015, 126, 749-749.	1.4	2
106	New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting. , 2015, 12, .		0
107	Novel Epigenetic Modulators That Promote Fetal Hemoglobin Production for the Prevention of Sickle Cell Disease Related Complications. Blood, 2015, 126, 973-973.	1.4	0
108	Evaluating Causes of Back Pain in Patients with Sickle Cell Disease. Blood, 2015, 126, 4593-4593.	1.4	0

#	Article	IF	CITATIONS
109	Density-based separation in multiphase systems provides a simple method to identify sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14864-14869.	7.1	107
110	Management of sickle cell disease from childhood through adulthood. Blood Reviews, 2013, 27, 279-287.	5.7	122
111	A simple, rapid, low-cost diagnostic test for sickle cell disease. Lab on A Chip, 2013, 13, 1464.	6.0	72
112	A Simple, Rapid, Low-Cost Test for the Diagnosis of Sickle Cell Disease Using a Paper-Based Hemoglobin Solubility Assay. Blood, 2012, 120, 245-245.	1.4	4
113	The Cambridge Automated Neuropsychological Testing Automated Battery (CANTAB) Is Feasible and Valuable for the Evaluation of Neurocognitive Deficits in Pediatric Patients with Sickle Cell Disease: Results of a Pilot Study. Blood, 2011, 118, 4839-4839.	1.4	1
114	Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP). Blood, 2010, 116, 72-72.	1.4	4
115	Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity. Blood, 2010, 116, 4820-4820.	1.4	0
116	Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia. , 0, , 275275302110738.		0
117	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood, 0, , .	1.4	5